Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
Date:11/9/2009

SAN DIEGO, Nov. 9, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the third quarter ended September 30, 2009.

Arena reported a lower net loss allocable to common stockholders in the third quarter of 2009 of $34.8 million, or $0.38 per share, compared to a net loss allocable to common stockholders in the third quarter of 2008 of $56.2 million, or $0.76 per share, and a net loss allocable to common stockholders in the first nine months of 2009 of $123.4 million, or $1.51 per share, compared to a net loss allocable to common stockholders in the first nine months of 2008 of $177.0 million, or $2.40 per share.

"The successful completion of the lorcaserin pivotal program in the third quarter was a critical milestone for Arena," stated Jack Lief, Arena's President and Chief Executive Officer. "The positive results were received with support and enthusiasm at The Obesity Society's annual meeting last month. Participating physicians shared with us three clear themes: the pressing need for new weight management treatments, the paramount importance of safety in treating overweight and obese patients, and that weight reduction should translate into improvements in cardiometabolic health. If approved, the unique combination of efficacy, safety and tolerability positions lorcaserin as first-line therapy."

As expected, research and development expenses declined significantly to $22.1 million in the third quarter of 2009 from $47.5 million in the third quarter of 2008. Research and development expenses declined to $89.0 million in the first nine months of 2009 from $151.0 million in the first nine months of 2008. This decrease is primarily due to the completion of the BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) and BLOSSOM (Behav
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces that ... catalogue: Baby Food Eastern Europe 2014 ... Food Eastern Europe 2014" is a new report by ... in Eastern Europe , key segments, ... This report also examines trends which are currently affecting ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 ... new market research report is available ... Chinese Guidebook for Application and Approval ... Regulations to Practices (2014 Edition) ... Now, Chinese regulations ...
(Date:8/27/2014)... and NINGBO, China , Aug. 27, ... Menovo Pharmaceutical Co., Ltd, ("Menovo") today announced they had ... generic pharmaceuticals, primarily targeting the United States ... Amerigen and Menovo will jointly develop products for Amerigen ... . Menovo will be responsible for manufacturing API and ...
Breaking Medicine Technology:Baby Food Eastern Europe 2014 2Baby Food Eastern Europe 2014 3Baby Food Eastern Europe 2014 4Baby Food Eastern Europe 2014 5Baby Food Eastern Europe 2014 6Baby Food Eastern Europe 2014 7Baby Food Eastern Europe 2014 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 5Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 6Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 9Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 10Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2
(Date:8/28/2014)... 2014 Registration is now open for ... in Holmdel, New Jersey on Sunday, October 19, 2014. ... New Jersey Vietnam Veterans’ Memorial adjacent to the Vietnam ... Arts Center. All proceeds of the event will benefit ... restoring a sense of self, restoring the family unit, ...
(Date:8/28/2014)... graduate, rising star and The Voice Season 5 contestant Brandon ... for Pepsi’s Southern Original . He’s heading to Panama City ... coach from The Voice and country music superstar Blake Shelton. Chase ... 28th at 9:00 pm at Tootsie’s at Pier Park in Panama ... Gulf Coast Jam main stage on Sunday, August 31 at 4:30 ...
(Date:8/28/2014)... 2014 ChiLiving® will host its ... NC at holistic retreat center, Om Sanctuary. This ... Katherine and Danny Dreyer, offers beginner to seasoned ... that support a lifetime of pain-free, injury-free movement ... in the heart of the Blue Ridge Mountains ...
(Date:8/28/2014)... Houston, Texas (PRWEB) August 28, 2014 ... Program. The program is a chance for regular customers ... MMAR Medical without the need for a wholesale license. ... athletics coaches, semi-professional athletic programs and others who regularly ... point. , “Whether supporting your own active lifestyle ...
(Date:8/28/2014)... Fort Worth, Texas (PRWEB) August 28, 2014 ... experiencing significant growth over the past few years. The new ... - will offer higher quality and larger office space than ... for growth. , “We are pleased about our new ... Laurenzo said. “While our suite will be double in size ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Second Annual NJ Run 2Health News:Rising Star Brandon Chase Named Finalist in Pepsi Southern Original Contest 2Health News:Join ChiRunning® & ChiWalking® Creators, Katherine and Danny Dreyer, for First-ever ChiWeekend Retreat in Asheville, NC 2Health News:Join ChiRunning® & ChiWalking® Creators, Katherine and Danny Dreyer, for First-ever ChiWeekend Retreat in Asheville, NC 3Health News:MMAR Medical Announces Customer Membership Program 2
... Do adolescents get enough exercise and eat the right ... Researchers analyzed the behavior of almost 900 11-to-15 year-olds ... and dietary risk behaviors, almost half had at least ... of the health guidelines in the study. ...
... the protein EGFR are important for the development of lung ... However, not all individuals// express the same mutant EGFR, for ... of EGFR and some have a mutation that affects the ... ,The potential of therapeutics to benefit individuals with ...
... The most recent Cochrane Review concluded antidepressants bupropion (Zyban) ... smoking and have few side-effects, but selective Serotonin reuptake ... ,Although nicotine medications are known to ... them or wants to use them. One possible alternative ...
... new report finds that less number of women aged 40 ... declining mammography rate could mean more breast cancer deaths down ... rates kept increasing during the 1990s, and scientists are disturbed ... reminded that, despite mammography being a test that's been around ...
... women who take folic acid supplements during their early pregnancy ... baby up to 40%. The Study results were published in ... ,Folic acid, a synthetic compound of a B vitamin ... neural tube disorders such as spina bifida. But its impact ...
... Scientists at UC Irvine have discovered that learning appears to ... hallmarks of Alzheimer's disease.// The finding suggests that the elderly, ... of this degenerative disease. The study appears in the Jan. ... ,This study with genetically modified mice is the first to ...
Cached Medicine News:Health News:Assessing Diet and Exercise Behaviors in Adolescents 2Health News:Mammography Saves Life-Beware Women Over 40 2Health News:Folic Acid Reduces Risk Of Cleft Lip 2Health News:Learning Slows Physical Progression of Alzheimer's Disease: Study 2
Digital Ultrasonic Diagnostic Imaging System...
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Pefakit PiCT LMWH Controls...
Calcium Chloride 0.020M - 4 ml...
Medicine Products: